BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 15876951)

  • 21. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.
    Iro MA; Khatami A; Marshall AS; Pace D; Voysey M; McKenna J; Campbell D; Attard-Montalto S; Finn A; White C; Faust SN; Kent A; Heath PT; MacLeod E; Stanford E; Findlow H; Almond R; Bai X; Borrow R; Snape MD; Pollard AJ
    Lancet Infect Dis; 2015 Feb; 15(2):172-80. PubMed ID: 25577661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease.
    Berthet F; Prehn A; Suter R; Ethevenaux C; Seger RA
    Pediatr Allergy Immunol; 1998 Aug; 9(3):156-60. PubMed ID: 9814731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
    Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12-18 months of age.
    Habermehl P; Leroux-Roels G; Sänger R; Mächler G; Boutriau D
    Hum Vaccin; 2010 Aug; 6(8):640-51. PubMed ID: 20697200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose.
    Berrington JE; Cant AJ; Matthews JN; O'Keeffe M; Spickett GP; Fenton AC
    Pediatrics; 2006 Apr; 117(4):e717-24. PubMed ID: 16549502
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and safety of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, compared with Hiberix™ in Korean infants and children: a randomized trial.
    Kim KH; Kim YK; Kim NH; Chang SH; Lee J; Park EA; Park SE; Eun BW; Lee H; Lee HJ
    Vaccine; 2012 Feb; 30(10):1886-94. PubMed ID: 22245607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of reconstitution of an Haemophilus influenzae type b-tentanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up.
    Hoppenbrouwers K; Roelants M; Ethevenaux C; Vandermeulen C; Knops J; Desmyter J
    Vaccine; 1999 Jun; 17(20-21):2588-98. PubMed ID: 10418907
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Studies on a Hib-tetanus toxoid conjugate vaccine: effects of co-administered tetanus toxoid vaccine, of administration route and of combined administration with an inactivated polio vaccine.
    Carlsson RM; Claesson BA; Käyhty H; Selstam U; Iwarson S
    Vaccine; 1999 Oct; 18(5-6):468-78. PubMed ID: 10519936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neonatal immunization with diphtheria and tetanus toxoids on antibody responses to Haemophilus influenzae type b conjugate vaccines.
    Lieberman JM; Greenberg DP; Wong VK; Partridge S; Chang SJ; Chiu CY; Ward JI
    J Pediatr; 1995 Feb; 126(2):198-205. PubMed ID: 7844665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine.
    Schmitt HJ; Maechler G; Habermehl P; Knuf M; Saenger R; Begg N; Boutriau D
    Clin Vaccine Immunol; 2007 Apr; 14(4):426-34. PubMed ID: 17287313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a diphtheria, tetanus, acellular pertussis and Haemophilus influenzae Type b combination vaccine compared with separate administration of licensed equivalent vaccines in Chinese infants and toddlers for primary and booster immunization.
    Li G; Zhang H; Zhou W; Ye Q; Li F; Wang H; Hou Q; Xu Y; Ma X; Tan Y; Wang L; Li Y; Li H; Meng F; Liang Q; Liu A; Qin C; Wei W; Liu J; Ruan C; Tao W; Zhang S; Zheng H; Zhu F
    Vaccine; 2010 Jun; 28(25):4215-23. PubMed ID: 20399240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy.
    Kurikka S; Olander RM; Eskola J; Käyhty H
    Pediatr Infect Dis J; 1996 Jun; 15(6):530-5. PubMed ID: 8783351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
    Carlsson RM; Claesson BA; Selstam U; Fagerlund E; Granström M; Blondeau C; Hoffenbach A
    Pediatr Infect Dis J; 1998 Nov; 17(11):1026-33. PubMed ID: 9849987
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunological response of Thai infants to haemophilus influenzae type B polysaccharide-tetanus conjugate vaccine co-administered in the same syringe with locally produced diphtheria-tetanus-pertussis vaccine.
    Kerdpanich A; Hutagalung Y; Watanaveeradej V; Bock HL; Steinhoffmd M
    J Med Assoc Thai; 2007 Jul; 90(7):1330-6. PubMed ID: 17710973
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine.
    Eskola J; Olander RM; Hovi T; Litmanen L; Peltola S; Käyhty H
    Lancet; 1996 Dec 21-28; 348(9043):1688-92. PubMed ID: 8973430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine.
    Southern J; Crowley-Luke A; Borrow R; Andrews N; Miller E
    Vaccine; 2006 Jan; 24(2):215-9. PubMed ID: 16112255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.